Core Insights - NeuroBo Pharmaceuticals has entered a joint research agreement with Dong-A ST and ImmunoForge to develop a long-acting formulation of DA-1726, a dual oxyntomodulin (OXM) analog agonist for obesity treatment, utilizing ImmunoForge's ELP platform technology which can increase a drug's half-life by up to 200 times [1][2][3] Company Overview - NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and DA-1726 for obesity treatment [6][7] - ImmunoForge specializes in novel drug development with a pipeline that includes candidates in pre-clinical through Phase 2 stages, leveraging its patented ELP platform technology [3] Product Details - DA-1726 is designed as a once-weekly subcutaneous injection that acts as a dual agonist of GLP-1 receptors and glucagon receptors, leading to weight loss through appetite reduction and increased energy expenditure [5][6] - Pre-clinical studies indicate that DA-1726 has shown improved weight loss compared to other treatments like semaglutide and cotadutide, while preserving lean body mass and demonstrating better lipid-lowering effects [5]
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity